Clinical Trial Update: Study of the Effects of High-dose N-acetylcysteine (NAC) in Idiopathic Pulmonary Fibrosis (IPF) [Phase 3]

View source ↗

Summary

This document notes the completion of a Phase 3 study evaluating high-dose N-acetylcysteine in idiopathic pulmonary fibrosis, sponsored by Zambon SpA.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis
• Pulmonary Fibrosis

Drugs mentioned

• N-acetylcysteine (N-acetylcysteine)

Snippet

Sponsor: Zambon SpA | Conditions: Pulmonary Fibrosis | Phase 3 | Status: COMPLETED